1. Ranibizumab Combined With Low-Dose Sorafenib for Exudative Age-Related Macular Degeneration 
Teresa Diago, MD, Jose S. Pulido, MD, MPH, MS, Julian R. Molina, MD, PhD, Lucienne C. Collet, MD, Thomas P. Link, CRA, Edwin H. Ryan, MD 
Mayo Clinic Proceedings 
Volume 83, Issue 2, Pages (February 2008)
DOI: /
Copyright © 2008 Mayo Foundation for Medical Education and Research Terms and Conditions

2. FIGURE 1
Case 1. A, Timeline of treatment with ranibizumab and/or sorafenib from September 2005 to September B, Initial fluorescein angiogram reveals leakage consistent with a neovascular membrane. C, Optical coherence tomogram confirms the presence of intraretinal fluid (arrow) before combined therapy was given. D, Optical coherence tomogram shows no intraretinal fluid 1 month after combined therapy. E, Recurrence of intraretinal fluid (arrow) 2 months after discontinuation of sorafenib. F, Optical coherence tomogram shows no intraretinal fluid 1 month after reinstitution of sorafenib.
Mayo Clinic Proceedings  , DOI: ( / )
Copyright © 2008 Mayo Foundation for Medical Education and Research Terms and Conditions

3. FIGURE 2
Case 2. Timeline of treatment with ranibizumab and/or sorafenib from September 2005 to September B, Initial fluorescein angiogram shows leakage consistent with a neovascular membrane. C, Optical coherence tomogram confirms presence of intraretinal fluid (arrow) 2 months after ranibizumab injection. D, Optical coherence tomogram shows intraretinal fluid (arrow) 1 month after ranibizumab injection. E, Optical coherence tomogram shows no intraretinal fluid 1 month after administration of sorafenib.
Mayo Clinic Proceedings  , DOI: ( / )
Copyright © 2008 Mayo Foundation for Medical Education and Research Terms and Conditions